Potential new colorectal cancer treatment target identified

October 7, 2012
Potential new colorectal cancer treatment target identified
The cell surface marker carcinoembryonic antigen-related cell adhesion molecule 6 is a novel marker for colorectal cancer stem cell isolation, which halts tumor growth when silenced, according to research published online Oct. 1 in Cancer.

(HealthDay)—The cell surface marker carcinoembryonic antigen-related cell adhesion molecule 6 (CD66c) is a novel marker for colorectal cancer stem cell isolation, which halts tumor growth when silenced, according to research published online Oct. 1 in Cancer.

Marica Gemei, Ph.D., of CEINGE-Advanced Biotechnology in Naples, Italy, and colleagues characterized CD66c expression in colorectal cancer stem cells by and immunohistochemistry in colon cancer samples and normal tissue. They evaluated its expression in colon cancer stem cells and in stem cell-enriched colon spheres and examined the role of RNA-mediated CD66c silencing on the in vitro and in vivo growth of Caco2 .

Compared with normal colon tissues, the researchers found that CD66c expression was significantly higher in colorectal cancer samples, with expression correlating with cancer stage. Its expression was absent in Prominin 1 (CD133)-positive cells from normal colon but was brightest (CD66cbright) in CD133-positive colon cancer samples. In vitro experiments in stem cell-enriched colon spheres exhibited cells expressing CD66cbright, similar to that observed in fresh . In Caco2 cells, CD66c silencing hampered in vitro proliferation and clonogenic potential, and in vivo xenograft experimentation attenuated the tumorigenic potential of Caco2 cells.

"CD66cbright expression was associated with colon cancer stem cells and CD66c silencing blocked tumor growth, thereby opening the way to a potential new treatment for colon cancer," the authors write.

Explore further: Whole grape - seed and skin - may be perfect colon cancer fighting food

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Whole grape - seed and skin - may be perfect colon cancer fighting food

June 2, 2011
(Medical Xpress) -- Colorado State University researchers may have unlocked the secret to why drinking wine and eating grapes can fight colon cancer. The study looks at how two grape compounds work in conjunction to kill ...

UH researchers explore treatments for breast and colon cancers

August 22, 2011
University of Houston (UH) researchers have their sights set on developing possible treatments for breast and colon cancer.

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.